Luxmatra is working in the area of developing novel mRNA vaccines and nanoparticle based immune-enhancing adjuvants for cancer immunotherapy and infectious disease. It is currently funded by BIRAC and Angel Investors from USA. LuxMatra Licensed a nano-vaccine technology from Amrita Vishwa Vidyapeetham University, for clinical development. The business plan of Luxmatra is to build an mRNA therapeutics company for viral infections and Cancer.